Cargando…
Glycopeptides as Potential Interventions for COVID-19
Coronavirus disease 2019 (COVID-19), an infectious disease that primarily attacks the human pulmonary system, is caused by a viral strain called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The outbreak emerged from Wuhan, China, and later spread throughout the world. Until the firs...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569252/ https://www.ncbi.nlm.nih.gov/pubmed/33116397 http://dx.doi.org/10.2147/BTT.S262705 |
_version_ | 1783596692833042432 |
---|---|
author | Demsie, Desalegn Getnet Gebre, Abadi Kahsu Yimer, Ebrahim M Alema, Niguse Meles Araya, Ephrem Mebrahtu Bantie, Abere Tilahun Allene, Mengesha Dessie Gebremedhin, Hagazi Yehualaw, Adane Tafere, Chernet Tadese, Haileslassie Tesfay Amare, Bekalu Weldekidan, Etsay Gebrie, Desye |
author_facet | Demsie, Desalegn Getnet Gebre, Abadi Kahsu Yimer, Ebrahim M Alema, Niguse Meles Araya, Ephrem Mebrahtu Bantie, Abere Tilahun Allene, Mengesha Dessie Gebremedhin, Hagazi Yehualaw, Adane Tafere, Chernet Tadese, Haileslassie Tesfay Amare, Bekalu Weldekidan, Etsay Gebrie, Desye |
author_sort | Demsie, Desalegn Getnet |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19), an infectious disease that primarily attacks the human pulmonary system, is caused by a viral strain called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The outbreak emerged from Wuhan, China, and later spread throughout the world. Until the first week of May 2020, over 3.7 million cases had been reported worldwide and more than 258,000 had died due to the disease. So far, off label use of various drugs has been tried in many clinical settings, however, at present, there is no vaccine or antiviral treatment for human and animal coronaviruses. Therefore, repurposing of the available drugs may be promising to control emerging infections of SARS-COV2; however, new interventions are likely to require months to years to develop. Glycopeptides, which are active against gram-positive bacteria, have demonstrated significant activity against viral infections including SARS-COV and MERS-COV and have a high resemblance of sequence homology with SARS-COV2. Recent in vitro studies have also shown promising activities of aglycon derivative of glycopeptides and teicoplanin against SARS-COV2. Hydrophobic aglycon derivatives and teicoplanin, with minimal toxicity to human cell lines, inhibit entry and replication of SARS-COV2. These drugs block proteolysis of polyprotein a/b with replicase and transcription domains. Teicoplanin use was associated with complete viral clearance in a cohort of patients with severe COVID-19 symptoms. This review attempts to describe the activity, elucidate the possible mechanisms and potential clinical applications of existing glycopeptides against corona viruses, specifically SARS-COV2. |
format | Online Article Text |
id | pubmed-7569252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75692522020-10-27 Glycopeptides as Potential Interventions for COVID-19 Demsie, Desalegn Getnet Gebre, Abadi Kahsu Yimer, Ebrahim M Alema, Niguse Meles Araya, Ephrem Mebrahtu Bantie, Abere Tilahun Allene, Mengesha Dessie Gebremedhin, Hagazi Yehualaw, Adane Tafere, Chernet Tadese, Haileslassie Tesfay Amare, Bekalu Weldekidan, Etsay Gebrie, Desye Biologics Review Coronavirus disease 2019 (COVID-19), an infectious disease that primarily attacks the human pulmonary system, is caused by a viral strain called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The outbreak emerged from Wuhan, China, and later spread throughout the world. Until the first week of May 2020, over 3.7 million cases had been reported worldwide and more than 258,000 had died due to the disease. So far, off label use of various drugs has been tried in many clinical settings, however, at present, there is no vaccine or antiviral treatment for human and animal coronaviruses. Therefore, repurposing of the available drugs may be promising to control emerging infections of SARS-COV2; however, new interventions are likely to require months to years to develop. Glycopeptides, which are active against gram-positive bacteria, have demonstrated significant activity against viral infections including SARS-COV and MERS-COV and have a high resemblance of sequence homology with SARS-COV2. Recent in vitro studies have also shown promising activities of aglycon derivative of glycopeptides and teicoplanin against SARS-COV2. Hydrophobic aglycon derivatives and teicoplanin, with minimal toxicity to human cell lines, inhibit entry and replication of SARS-COV2. These drugs block proteolysis of polyprotein a/b with replicase and transcription domains. Teicoplanin use was associated with complete viral clearance in a cohort of patients with severe COVID-19 symptoms. This review attempts to describe the activity, elucidate the possible mechanisms and potential clinical applications of existing glycopeptides against corona viruses, specifically SARS-COV2. Dove 2020-10-13 /pmc/articles/PMC7569252/ /pubmed/33116397 http://dx.doi.org/10.2147/BTT.S262705 Text en © 2020 Demsie et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Demsie, Desalegn Getnet Gebre, Abadi Kahsu Yimer, Ebrahim M Alema, Niguse Meles Araya, Ephrem Mebrahtu Bantie, Abere Tilahun Allene, Mengesha Dessie Gebremedhin, Hagazi Yehualaw, Adane Tafere, Chernet Tadese, Haileslassie Tesfay Amare, Bekalu Weldekidan, Etsay Gebrie, Desye Glycopeptides as Potential Interventions for COVID-19 |
title | Glycopeptides as Potential Interventions for COVID-19 |
title_full | Glycopeptides as Potential Interventions for COVID-19 |
title_fullStr | Glycopeptides as Potential Interventions for COVID-19 |
title_full_unstemmed | Glycopeptides as Potential Interventions for COVID-19 |
title_short | Glycopeptides as Potential Interventions for COVID-19 |
title_sort | glycopeptides as potential interventions for covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569252/ https://www.ncbi.nlm.nih.gov/pubmed/33116397 http://dx.doi.org/10.2147/BTT.S262705 |
work_keys_str_mv | AT demsiedesalegngetnet glycopeptidesaspotentialinterventionsforcovid19 AT gebreabadikahsu glycopeptidesaspotentialinterventionsforcovid19 AT yimerebrahimm glycopeptidesaspotentialinterventionsforcovid19 AT alemanigusemeles glycopeptidesaspotentialinterventionsforcovid19 AT arayaephremmebrahtu glycopeptidesaspotentialinterventionsforcovid19 AT bantieaberetilahun glycopeptidesaspotentialinterventionsforcovid19 AT allenemengeshadessie glycopeptidesaspotentialinterventionsforcovid19 AT gebremedhinhagazi glycopeptidesaspotentialinterventionsforcovid19 AT yehualawadane glycopeptidesaspotentialinterventionsforcovid19 AT taferechernet glycopeptidesaspotentialinterventionsforcovid19 AT tadesehaileslassietesfay glycopeptidesaspotentialinterventionsforcovid19 AT amarebekalu glycopeptidesaspotentialinterventionsforcovid19 AT weldekidanetsay glycopeptidesaspotentialinterventionsforcovid19 AT gebriedesye glycopeptidesaspotentialinterventionsforcovid19 |